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early distal tubule fluid is not K secretion at the early DCT,
but rather a reduction in K reabsorption in the TAL.
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To the Editor: The recent in vitro studies of the Slatopolsky
group1 have shown that the ‘non active’ 25-OH-vitamin D
metabolite was actually efficient (even though less potent) at
physiological concentration for suppressing parathyroid
hormone synthesis by direct stimulation of the vitamin D
receptor, and that this direct stimulation was even pre-
ponderant over that induced by 1,25(OH) vitamin D3
produced in situ. This is consistent with our earlier reports
evidencing (1) in predialysis patients,2 a good long-term
control of hyperparathyroid bone disease by just normocal-
cemic dose of 25-OH-vitamin D in association with up to
2.4 g/day of CaCO3 and (2) in dialysis patients,
3 an
independent inverse link between parathyroid hormone and
25-OH-vitamin D serum concentrations independently of
serum concentrations of calcitriol, calcium, and phosphate.
This challenges the NKF-K/DOQI recommendation for
suppressing intact parathyroid hormone 4300 pg/ml in
dialysis patients, to inject hypercalcemic and hyperpho-
sphatemic dose of calcitriol and paricalcitol, instead of
correcting the highly prevalent (87%) vitamin D deficiency in
American patients. This correction would decrease the need
of ‘active’ vitamin D derivatives for this suppression, while
better preventing vascular calcification (in spite of concomi-
tant use of calcium–phosphate binder) as suggested by the
comparison of the two cohorts of young adults with
childhood-onset of end-stage renal disease, as quoted in
our letter to Kidney International about Kalantar-Zadeh
article,4 pointing out that the survival benefit granted by
paricalcitol was inversely related to its dose.
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The letter from Shahapuni et al.1 cites our finding that
25-hydroxyvitamin D3 (25(OH)D3) suppresses parathyroid
hormone (PTH) synthesis in cultured parathyroid cells2 to
emphasize earlier studies from their group (1) demonstrat-
ing the skeletal benefits of improving vitamin D status in
chronic kidney disease patients, and (2) the inverse
correlation of PTH with 25(OH)D3 but not with calcitriol
in dialysis patients, relationships that have also been
documented in the general population.3
In response, we feel it necessary to clarify two points in
the letter. First, the authors incorrectly state that our data
showed that 25(OH)D3 produced a greater decrease in PTH
than calcitriol. In fact, the maximal reduction in both PTH
secretion and PTH mRNA was not different. Second, the K/
DOQI guidelines do not recommend injecting hypercalce-
mic or hyperphosphatemic doses of calcitriol or its analogs
as stated in the letter. The algorithms clearly state the
target ranges for plasma Ca and P and suggest modifica-
tions when they are exceeded.
The K/DOQI guidelines recommend ergocalciferol
supplementation in predialysis patients with 25(OH)D3
levels less than 30 ng/ ml, but as Shahapuni et al. point out,
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no such recommendation is made for dialysis patients. The
reasoning for this may be that the lack of renal function
would preclude conversion to the active 1,25(OH)2D2,
although there is some evidence that extrarenal sources
can increase 1,25(OH)2D in supplemented anephric
patients.4,5 The data in our study suggest the potential
for a direct suppressive action of 25(OH)D3 on the
parathyroid glands in vivo. Clearly, clinical trials are
necessary to determine the utility of high-dose ergocalci-
ferol supplementation in the control of PTH levels in
dialysis patients.
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To the Editor: I would like to congratulate Dr Kalantar-
Zadeh and his colleagues on an excellent study concerning
the influence of calcium, phosphate, and parathyroid
hormone (PTH) on dialysis mortality.1
I do, however, have one supplementary question. Most
patients with a low PTH (o150 ng/ml) will have adynamic
bone disease (ABD). The conventional concept of ABD is that
it is an iatrogenic disease caused by oversuppression of PTH
by excessive use of calcium-containing phosphate binders
and active vitamin D. Thus the Kidney Disease Outcomes
Quality Initiative (K/DOQI) guidelines for ABD2 recom-
mend that calcium levels be reduced by reducing the dose of
calcium-based phosphate binders and vitamin D, in order to
stimulate the production of PTH.
From a clinical point of view, this conclusion is puzzling.
Most patients with ABD, as assessed by low PTH, are
characterized by higher age, and a high incidence of
comorbidity, malnutrition, and hypoalbuminemia.3,4 These
are the characteristic hallmarks of malnutrition–inflamma-
tion–cachexia syndrome, MICS (aka malnutrition–inflamma-
tion–atherosclerosis syndrome). These patients will therefore
have a lower requirement for phosphate binders and vitamin
D; indeed, many do not require any therapy at all. There is
therefore an alternative to the ‘iatrogenic’ theory, viz. that
ABD is just a surrogate marker of MICS, and that most of the
increased mortality and comorbidity associated with ABD is
caused by MICS. This has the practical consequence that
‘oversuppression’ of PTH is not as dangerous as implied by
K/DOQI. Support for this position can be found in the recent
study by Block et al.5 where low PTH was a risk factor for
death on an unadjusted analysis, but was associated with
better survival after adjustment for MICS. Furthermore, in a
recent study by Teng et al.6 treatment with vitamin D was
associated with a circa 20% better survival in patients with
low PTH, precisely the group where vitamin D treatment is
supposed to be contraindicated.
Figure 4 in the Kalantar-Zadeh paper lends some support
to this hypothesis, but also suggests that it cannot be the
entire explanation, in that MICS only partly accounted for
the increased mortality of patients with low PTH. One
particular problem that ABD patients may have had in this
study is an increased risk of hypercalcemia due to the lack of
bone buffer function. This should no longer be a problem in
the future due to the introduction of calcium-free phosphate
binders. An analysis was also performed for the effects of
changes in calcium and phosphate in patients starting within
the K/DOQI guidelines for calcium and phosphate (Figure
6). A similar analysis for groups of patients starting with
different levels of PTH could also be performed. The
mortality effects of changes in PTH in these groups, corrected
for (a) case mix, (b) MICS, (c) changes in plasma calcium
and phosphate, (d) combinations, would provide consider-
able support (or the opposite) for the K/DOQI guidelines
concerning PTH.
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